{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.1","upperLimit":"28.1","value":"19.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Duration of response is defined for all evaluable patients who have achieved a confirmed response as the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression (PD) is documented. The distribution of duration of response will be estimated using the method of Kaplan-Meier. (CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by ≥50% of previously involved sites from nadir).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral 40 mg panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (LBH589)"}],"paramType":"MEDIAN","populationDescription":"Patients who achieved a confirmed response were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Every 6 months for up to 2 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}